Methods of activating regulatory t cells
AssigneeHCW Biologics, Inc.
InventorsHing C. Wong, Niraj Shresha, Varghese George, Michael Dee
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of stimulating or increasing the proliferation of a Treg cell, compositions including a population of Treg cells generated by these methods, and methods of treating a subject using these compositions.
Claims72
A method of stimulating or increasing the proliferation of a Treg cell, wherein the method comprises:
- culturing a Treg cell in a liquid culture medium over a period of time, wherein at the beginning of the period of time, the liquid culture medium comprises:
- a CD3/CD28-binding agent;
- and
- a single-chain chimeric polypeptide comprising a first target-binding domain, a soluble tissue factor domain, and a second target-binding domain, wherein the first target-binding domain and the second target-binding domain bind to a receptor for IL-2.
-22. (canceled)
-32. (canceled)
-35. (canceled)
-69. (canceled)
-120. (canceled)
-126. (canceled)
-133. (canceled)
A kit comprising:
- (i) a CD3/CD28-binding agent;
- (ii) a single-chain chimeric polypeptide comprising a first target-binding domain, a soluble tissue factor domain, and a second target-binding domain, wherein the first target-binding domain and the second target-binding domain bind to a receptor for IL-2;
- and
- (iii) an mTOR inhibitor.
-140. (canceled)
A method of stimulating or increasing the proliferation of a Treg cell, wherein the method comprises:
- culturing a Treg cell in a liquid culture medium over a period of time, wherein at the beginning of the period of time, the liquid culture medium comprises:
- an IL-2 receptor-activating agent;
- and
- a single-chain chimeric polypeptide comprising a first target-binding domain, a soluble tissue factor domain, and a second target-binding domain, wherein:
- the first target-binding domain of the additional single-chain chimeric polypeptide binds to CD3 and the second target-binding domain of the additional single-chain chimeric polypeptide binds to CD28.
-181. (canceled)
-192. (canceled)
-198. (canceled)
-205. (canceled)
A kit comprising:
- (i) an interleukin-2 receptor-activating agent;
- (ii) a single-chain chimeric polypeptide comprising a first target-binding domain, a soluble tissue factor domain, and a second target-binding domain, wherein:
- the first target-binding domain binds to CD3 and the second target-binding domain binds to CD28;
- and
- (iii) an mTOR inhibitor.
(canceled)
A method of stimulating or increasing the proliferation of a Treg cell, wherein the method comprises:
- culturing a Treg cell in a liquid culture medium over a period of time, wherein at the beginning of the period of time, the liquid culture medium comprises:
- a CD3/CD28-binding agent;
- and
- a multi-chain chimeric polypeptide comprising:
- (a) a first chimeric polypeptide comprising:
- (i) a first target-binding domain;
- (ii) a soluble tissue factor domain;
- and
- (iii) a first domain of a pair of affinity domains;
- and
- (b) a second chimeric polypeptide comprising:
- (i) a second domain of a pair of affinity domains;
- and
- (ii) a second target-binding domain,
- wherein the first chimeric polypeptide and the second chimeric polypeptide associate through the binding of the first domain and the second domain of the pair of affinity domains.
-240. (canceled)
-243. (canceled)
-277. (canceled)
-317. (canceled)
-328. (canceled)
-334. (canceled)
-341. (canceled)
A kit comprising:
- a CD3/CD28-binding agent;
- a multi-chain chimeric polypeptide comprising:
- (a) a first chimeric polypeptide comprising:
- (i) a first target-binding domain;
- (ii) a soluble tissue factor domain;
- and
- (iii) a first domain of a pair of affinity domains;
- (b) a second chimeric polypeptide comprising:
- (i) a second domain of a pair of affinity domains;
- and
- (ii) a second target-binding domain,
- wherein the first chimeric polypeptide and the second chimeric polypeptide associate through the binding of the first domain and the second domain of the pair of affinity domains;
- and
- an mTOR inhibitor.
-348. (canceled)
A method of isolating a Treg cell from a sample obtained from a subject, wherein the method comprises separating the Treg cell from the sample based on its expression of CD39, thereby isolating the Treg cell.
-359. (canceled)
(canceled)
-367. (canceled)
Dependencies are inferred from the claim text.